Arbutus Biopharma Corporation Company Profile (NASDAQ:ABUS)

About Arbutus Biopharma Corporation (NASDAQ:ABUS)

Arbutus Biopharma Corporation logoArbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV). It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology. The Company's lead RNAi HBV candidate, ARB-1467, eliminates HBV surface antigen expression in patients chronically infected with HBV. ARB-1467 is being developed as a multi-component RNAi therapeutic that targets various sites on the HBV genome. It is also developing small molecule covalently closed circular deoxyribonucleic acid (cccDNA) formation inhibitors, multiple small molecule orally bioavailable inhibitors of HBV surface antigen production and secretion, cccDNA epigenetic modifiers and stimulator of interferon genes agonists.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ABUS
  • CUSIP: N/A
  • Web: www.arbutusbio.com
Capitalization:
  • Market Cap: $352.17 million
  • Outstanding Shares: 55,026,000
Average Prices:
  • 50 Day Moving Avg: $6.17
  • 200 Day Moving Avg: $4.21
  • 52 Week Range: $2.35 - $8.25
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.61
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.85 million
  • Price / Sales: 193.33
  • Book Value: $3.19 per share
  • Price / Book: 2.04
Profitability:
  • EBITDA: ($65,740,000.00)
  • Return on Equity: -28.97%
  • Return on Assets: -21.71%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 8.92%
  • Quick Ratio: 8.92%
Misc:
  • Average Volume: 321,092 shs.
  • Beta: 1.01
  • Short Ratio: 9.83
 

Frequently Asked Questions for Arbutus Biopharma Corporation (NASDAQ:ABUS)

What is Arbutus Biopharma Corporation's stock symbol?

Arbutus Biopharma Corporation trades on the NASDAQ under the ticker symbol "ABUS."

How were Arbutus Biopharma Corporation's earnings last quarter?

Arbutus Biopharma Corporation (NASDAQ:ABUS) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.11. The business had revenue of $4.10 million for the quarter, compared to analysts' expectations of $3.37 million. View Arbutus Biopharma Corporation's Earnings History.

When will Arbutus Biopharma Corporation make its next earnings announcement?

Arbutus Biopharma Corporation is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Arbutus Biopharma Corporation.

Where is Arbutus Biopharma Corporation's stock going? Where will Arbutus Biopharma Corporation's stock price be in 2017?

5 equities research analysts have issued 12-month price targets for Arbutus Biopharma Corporation's stock. Their forecasts range from $6.00 to $32.00. On average, they anticipate Arbutus Biopharma Corporation's stock price to reach $15.00 in the next twelve months. View Analyst Ratings for Arbutus Biopharma Corporation.

What are analysts saying about Arbutus Biopharma Corporation stock?

Here are some recent quotes from research analysts about Arbutus Biopharma Corporation stock:

  • 1. According to Zacks Investment Research, "Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC. " (7/10/2017)
  • 2. Wedbush analysts commented, "We believe ABUS remains undervalued ahead of key clinical readouts in 2017 for its HBV pipeline candidates, a mid:17 readout of Alnylam's Ph 3 patisiran study in ATTR that could lead to a significant royalties to ABUS, and the potential for additional partnerships around its attractive LNP platform." (3/22/2017)

Who are some of Arbutus Biopharma Corporation's key competitors?

Who are Arbutus Biopharma Corporation's key executives?

Arbutus Biopharma Corporation's management team includes the folowing people:

  • Vivek Ramaswamy, Chairman of the Board
  • Mark J. Murray Ph.D., President, Chief Executive Officer, Director
  • Bruce G. Cousins, Chief Financial Officer, Executive Vice President
  • Elizabeth Howard, Executive Vice President, General Counsel
  • Peter Lutwyche Ph.D., Chief Technology Officer
  • Michael Joseph Sofia, Chief Scientific Officer
  • William Thomas Symonds III, Chief Development Officer, Director
  • Michael J. Abrams Ph.D., Managing Director - Non-HBV Assets
  • Patrick T. Higgins, Chief Business Officer
  • Daniel D. Burgess, Director

How do I buy Arbutus Biopharma Corporation stock?

Shares of Arbutus Biopharma Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arbutus Biopharma Corporation's stock price today?

One share of Arbutus Biopharma Corporation stock can currently be purchased for approximately $6.50.


MarketBeat Community Rating for Arbutus Biopharma Corporation (NASDAQ ABUS)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  223 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Arbutus Biopharma Corporation (NASDAQ:ABUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $15.00 (130.77% upside)
Consensus Price Target History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Price Target History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Analysts' Ratings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/4/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $13.00HighView Rating Details
9/20/2017WedbushReiterated RatingOutperform$9.00MediumView Rating Details
9/13/2017Chardan CapitalReiterated RatingBuyHighView Rating Details
6/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$32.00LowView Rating Details
1/9/2017Bloom BurtonUpgradeAccumulate -> BuyN/AView Rating Details
8/21/2016William BlairReiterated RatingOutperformN/AView Rating Details
8/17/2016Leerink SwannDowngradeOutperform -> Market PerformN/AView Rating Details
12/21/2015Royal Bank Of CanadaLower Price Target$20.00 -> $12.00N/AView Rating Details
(Data available from 10/21/2015 forward)

Earnings

Earnings History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Earnings by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Earnings History by Quarter for Arbutus Biopharma Corporation (NASDAQ ABUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017($0.37)N/AView Earnings Details
5/4/20173/31/2017($0.30)($0.34)$7.50 million$0.20 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.31)($0.42)$3.37 million$4.10 millionViewN/AView Earnings Details
8/5/2015Q2($0.25)($0.20)$3.77 million$3.40 millionViewN/AView Earnings Details
3/12/2015Q4 2014($0.32)($0.27)$6.12 million$4.40 millionViewN/AView Earnings Details
11/6/2014Q314($0.40)($0.39)$3.71 million$4.40 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.11)$3.72 million$1.80 millionViewN/AView Earnings Details
12/18/2013Q3($0.07)($0.12)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Arbutus Biopharma Corporation (NASDAQ:ABUS)
2017 EPS Consensus Estimate: ($1.54)
2018 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.38)($0.25)($0.30)
Q2 20173($0.42)($0.39)($0.40)
Q3 20173($0.43)($0.39)($0.41)
Q4 20173($0.44)($0.39)($0.42)
Q1 20182($0.38)($0.36)($0.37)
Q2 20182($0.39)($0.36)($0.38)
Q3 20182($0.40)($0.37)($0.39)
Q4 20182($0.41)($0.38)($0.40)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 67.04%
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Institutional Ownership by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Insider Trades by Quarter for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/3/2017Michael J SofiaInsiderSell10,000$8.00$80,000.00View SEC Filing  
8/15/2017Michael J SofiaInsiderSell30,000$3.70$111,000.00View SEC Filing  
8/24/2015Richard C Henriques JrDirectorBuy1,000$6.95$6,950.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Latest Headlines for Arbutus Biopharma Corporation (NASDAQ:ABUS)
Source:
DateHeadline
seekingalpha.com logoArbutus out-licenses LNP technology to Gritstone Oncology - Seeking Alpha
seekingalpha.com - October 18 at 3:42 PM
streetinsider.com logoArbutus Biopharma (ABUS) and Gritstone Oncology Reports LNP ... - StreetInsider.com
www.streetinsider.com - October 18 at 3:42 PM
finance.yahoo.com logoGritstone Oncology and Arbutus Biopharma Announce LNP Technology Licensing Agreement to Develop Novel RNA-Based Personalized Neoantigen Immunotherapies for Cancer Patients
finance.yahoo.com - October 18 at 3:42 PM
finance.yahoo.com logoBucks biopharm firm signs licensing deal with California onco-immunology company
finance.yahoo.com - October 18 at 3:42 PM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) Expected to Post Quarterly Sales of $790,000.00
www.americanbankingnews.com - October 17 at 6:50 AM
globenewswire.com logoArbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences - GlobeNewswire (press release)
globenewswire.com - October 16 at 3:32 PM
finance.yahoo.com logoArbutus Announces Closing of $50 Million First Tranche of $116.4 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 16 at 3:32 PM
americanbankingnews.com logoContrasting Arbutus Biopharma Corporation (ABUS) & Organovo Holdings (ONVO)
www.americanbankingnews.com - October 16 at 10:58 AM
americanbankingnews.com logoArbutus Biopharma Corp (ABUS) Expected to Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - October 15 at 2:24 PM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 4:46 PM
americanbankingnews.com logoInsider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - October 5 at 7:44 PM
rttnews.com logoArbutus Biopharma Corp. (ABUS) Has Broken Out To A New High For The Year
www.rttnews.com - October 4 at 3:10 PM
americanbankingnews.com logoJMP Securities Reaffirms "Outperform" Rating for Arbutus Biopharma Corporation (ABUS)
www.americanbankingnews.com - October 4 at 1:42 PM
americanbankingnews.com logoArbutus Biopharma Corporation to Post Q1 2018 Earnings of ($0.38) Per Share, Wedbush Forecasts (ABUS)
www.americanbankingnews.com - October 4 at 11:04 AM
seekingalpha.com logoArbutus Biopharma: Updates To Thesis Part 2 - Seeking Alpha
seekingalpha.com - October 4 at 8:12 AM
globenewswire.com logoArbutus to Present HBV Data at 2017 AASLD Liver Meeting - GlobeNewswire (press release)
globenewswire.com - October 3 at 3:06 PM
finance.yahoo.com logoArbutus to Present HBV Data at 2017 AASLD Liver Meeting
finance.yahoo.com - October 3 at 3:06 PM
bizjournals.com logo$116M deal for Bucks County company working on hepatitis B cure
www.bizjournals.com - October 2 at 3:11 PM
streetinsider.com logoArbutus Biopharma (ABUS) Receives $116M Strategic Investment from Roivant Sciences
www.streetinsider.com - October 2 at 3:10 PM
finance.yahoo.com logoArbutus Announces Topline Results for ARB-1467 Phase II Cohort 4
finance.yahoo.com - October 2 at 3:10 PM
finance.yahoo.com logoArbutus to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - October 2 at 3:10 PM
finance.yahoo.com logoArbutus to Receive $116 Million Strategic Investment from Roivant Sciences
finance.yahoo.com - October 2 at 3:10 PM
finance.yahoo.com logoRoivant Makes $116 Million Investment In Arbutus, Backing Battle With Moderna
finance.yahoo.com - October 2 at 3:10 PM
americanbankingnews.com logoHead to Head Comparison: Arbutus Biopharma Corporation (ABUS) and Its Peers
www.americanbankingnews.com - October 2 at 12:22 PM
americanbankingnews.com logo Analysts Expect Arbutus Biopharma Corporation (ABUS) to Announce -$0.38 EPS
www.americanbankingnews.com - September 26 at 10:10 PM
feeds.benzinga.com logoArbutus Presents HBV Data at Upcoming Scientific Conferences
feeds.benzinga.com - September 22 at 5:49 PM
americanbankingnews.com logoWilliam Blair Weighs in on Arbutus Biopharma Corporation's Q1 2018 Earnings (ABUS)
www.americanbankingnews.com - September 22 at 9:00 AM
americanbankingnews.com logoArbutus Biopharma Corporation's (ABUS) Outperform Rating Reaffirmed at Wedbush
www.americanbankingnews.com - September 20 at 8:20 PM
finance.yahoo.com logoIs It Too Late To Buy Arbutus Biopharma Corporation (ABUS)?
finance.yahoo.com - September 20 at 3:19 PM
finance.yahoo.com logoArbutus’ LNP Licensee Alnylam Announces Positive Phase 3 Results for LNP-Enabled Patisiran Program
finance.yahoo.com - September 20 at 3:19 PM
seekingalpha.com logoArbutus Biopharma: Updates To Thesis - Seeking Alpha
seekingalpha.com - September 18 at 8:35 PM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 17 at 3:10 PM
americanbankingnews.com logoArbutus Biopharma Corporation (ABUS) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - September 17 at 1:20 AM
americanbankingnews.com logoArbutus Biopharma Corporation's (ABUS) "Buy" Rating Reiterated at Chardan Capital
www.americanbankingnews.com - September 16 at 7:18 AM
rttnews.com logoCompany Spotlight: Arbutus Biopharma
www.rttnews.com - September 16 at 1:32 AM
nasdaq.com logoCompany Spotlight: Arbutus Biopharma - Nasdaq
www.nasdaq.com - September 15 at 3:28 PM
nasdaq.com logoAlexion to Restructure Operations, to Lower Headcount by 20% - Nasdaq
www.nasdaq.com - September 13 at 8:31 PM
finance.yahoo.com logoAlexion to Restructure Operations, to Lower Headcount by 20%
finance.yahoo.com - September 13 at 8:31 PM
finance.yahoo.com logoArbutus: Potential Near-Term Catalysts and Pipeline Overview
finance.yahoo.com - September 12 at 3:23 PM
finance.yahoo.com logoArbutus to Host Live Webinar on Developments of LNP Delivery for mRNA-based Therapeutics
finance.yahoo.com - September 7 at 3:19 PM
finance.yahoo.com logoArbutus Biopharma Corp. :ABUS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 3:22 PM
seekingalpha.com logoTrading Arbutus Ahead Of Hepatitis B Data - Seeking Alpha
seekingalpha.com - August 22 at 8:41 PM
americanbankingnews.com logo$790,000.00 in Sales Expected for Arbutus Biopharma Corporation (ABUS) This Quarter
www.americanbankingnews.com - August 22 at 11:40 AM
americanbankingnews.com logoInsider Selling: Arbutus Biopharma Corporation (ABUS) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - August 17 at 10:48 PM
finance.yahoo.com logoArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 16 at 8:23 PM
globenewswire.com logoArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - August 14 at 3:28 PM
finance.yahoo.com logoArbutus to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 14 at 3:28 PM
americanbankingnews.com logoArbutus Biopharma Corporation (NASDAQ:ABUS) Rating Reiterated by Chardan Capital
www.americanbankingnews.com - August 7 at 8:00 AM
seekingalpha.com logoArbutus Biopharma Corp's (ABUS) CEO Mark Murray on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 4 at 8:29 PM
globenewswire.com logoArbutus Announces Corporate Update and Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 4 at 3:24 PM

Social

Chart

Arbutus Biopharma Corporation (ABUS) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.